That is an amazing article from November, it’s cool to see how their plans are coming to fruition. If Cannepil only gets 10% market share in Australia that’s $700mil in annual revenue, that doesn’t even include Europe. I would imagine a lot of people with epilepsy are waiting for this release. I want to find out how soon after the first 100 patients get this it goes to open market. I would imagine right away.
I bought more this morning. .062 is unreal for this potential- my guess end of year this is $1.50-$2.00. Aurora has half a billion shares out and valued almost $7 now, I think MGC revenue will far pass Aurora and MGC will not end up a commodity. With 9mil in the bank and strong revenue I also think MGC will be better than Aurora in that they won’t be doing capital raises to bring share price down (my opinion). The board will want this to just go, based on the performance shares issued- they will benifit for their hard work in the future
News 
Market Data 
Discover 
